CC Stock Analysis: Chemours | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.321m USD | 12M Return: 15.3% | US1638511089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.1M
EPS Trend: -93.3%
Qual. Beats: 0
Rev. Trend: -69.3%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Chemours Company is a U.S.-based, mid-cap specialty chemicals producer operating across three reporting segments: Thermal & Specialized Solutions (refrigerants and propellants marketed under the Freon and Opteon brands), Titanium Technologies (TiO2 white pigment sold as Ti-Pure for coatings, plastics, and paper laminates), and Advanced Performance Materials (fluoropolymer resins, membranes, and coatings sold under Teflon, Viton, Krytox, and Nafion). The company sells globally through direct sales, third-party agents, and distributor networks, and was incorporated in 2014 in Wilmington, Delaware.
Chemours was created as a spin-off from DuPont in 2015, which is why the companys IPO date of July 1, 2015 closely follows its incorporation. As a member of the GICS Materials sector (Diversified Chemicals sub-industry), Chemours competes in commodity-influenced markets such as TiO2, where pricing is driven by global supply-demand balances, as well as in higher-margin fluoroproduct niches tied to electronics, semiconductors, and energy applications. The refrigerants business in particular faces regulatory pressure from the Kigali Amendment and other HFC phase-down rules, which is reshaping demand toward next-generation low-global-warming-potential products like the Opteon line.
- TiO2 pigment pricing recovers on coatings demand rebound
- HFC refrigerant phase-down accelerates Opteon transition
- PFAS litigation costs pressure margins and cash flow
| Net Income: -304.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 2.47 > 1.0 |
| NWC/Revenue: 21.27% < 20% (prev 21.27%; Δ 0.00% < -1%) |
| CFO/TA 0.05 > 3% & CFO 353.0m > Net Income -304.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (151.4m) vs 12m ago 0.76% < -2% |
| Gross Margin: 15.34% > 18% (prev 18.25%; Δ -2.92% > 0.5%) |
| Asset Turnover: 79.20% > 50% (prev 78.50%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: -1.48 > 6 (EBIT TTM -404.0m / Interest Expense TTM 273.0m) |
| A: 0.17 (Total Current Assets 3.09b - Total Current Liabilities 1.86b) / Total Assets 7.15b |
| B: 0.12 (Retained Earnings 891.0m / Total Assets 7.15b) |
| C: -0.06 (EBIT TTM -404.0m / Avg Total Assets 7.32b) |
| D: -0.01 (Book Value of Equity -49.0m / Total Liabilities 7.20b) |
| Altman-Z'' = 1.16 = BB |
| DSRI: 0.96 (Receivables 907.0m/959.0m, Revenue 5.80b/5.88b) |
| GMI: 1.19 (GM 18.25% / 15.34%) |
| AQI: 0.81 (AQ_t 0.11 / AQ_t-1 0.13) |
| SGI: 0.99 (Revenue 5.80b / 5.88b) |
| TATA: -0.09 (NI -304.0m - CFO 353.0m) / TA 7.15b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of August 23, 2026, the stock is trading at USD 15.97 with a total of 1,184,655 shares traded. Over the past week, the price has changed by +0.76%, over one month by -10.36%, over three months by -25.08% and over the past year by +15.33%.
Current recommended Stop Loss: 13.80 (which is 13.6% or 2.3 ATR below the current price).
Chemours has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold CC.
- StrongBuy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.8 | 23.9% |
P/E Forward = 14.3472
P/S = 0.4003
P/B = 12.5408
P/EG = 1.6042
Revenue TTM = 5.80b USD
EBIT TTM = -404.0m USD
EBITDA TTM = -85.0m USD
Long Term Debt = 3.84b USD (from longTermDebt, last quarter)
Short Term Debt = 91.0m USD (from shortTermDebt, last quarter)
Debt = 4.37b USD (from shortLongTermDebtTotal, last quarter) + Leases 248.0m
Net Debt = 3.70b USD (calculated: Debt 4.37b - CCE 671.0m)
Enterprise Value = 6.02b USD (2.32b + Debt 4.37b - CCE 671.0m)
Interest Coverage Ratio = -1.48 (Ebit TTM -404.0m / Interest Expense TTM 273.0m)
EV/FCF = 48.14x (Enterprise Value 6.02b / FCF TTM 125.0m)
FCF Yield = 2.08% (FCF TTM 125.0m / Enterprise Value 6.02b)
FCF Margin = 2.16% (FCF TTM 125.0m / Revenue TTM 5.80b)
Net Margin = -5.24% (Net Income TTM -304.0m / Revenue TTM 5.80b)
Gross Margin = 15.34% ((Revenue TTM 5.80b - Cost of Revenue TTM 4.91b) / Revenue TTM)
Gross Margin QoQ = 17.98% (prev 15.57%)
Tobins Q-Ratio = 0.84 (Enterprise Value 6.02b / Total Assets 7.15b)
Interest Expense / Debt = 6.25% (Interest Expense 273.0m / Debt 4.37b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -319.2m (EBIT -404.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.66 (Total Current Assets 3.09b / Total Current Liabilities 1.86b)
Debt / Equity = -89.14 (negative equity) (Debt 4.37b / totalStockholderEquity, last quarter -49.0m)
Debt / EBITDA = -43.49 (negative EBITDA) (Net Debt 3.70b / EBITDA -85.0m)
Debt / FCF = 29.58 (Net Debt 3.70b / FCF TTM 125.0m)
Total Stockholder Equity = 178.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.15% (Net Income -304.0m / Total Assets 7.15b)
RoE = -170.3% (Net Income TTM -304.0m / Total Stockholder Equity 178.5m)
RoCE = -10.06% (EBIT -404.0m / Capital Employed (Equity 178.5m + L.T.Debt 3.84b))
RoIC = -6.27% (negative operating profit) (NOPAT -319.2m / Invested Capital 5.09b)
WACC = 7.24% (E(2.32b)/V(6.69b) * Re(11.56%) + D(4.37b)/V(6.69b) * Rd(6.25%) * (1-Tc(0.21)))
Discount Rate = 11.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.13 | Cagr: 0.39%
[DCF] Terminal Value 75.44% ; FCFF base≈125.0m ; Y1≈125.5m ; Y5≈133.0m
[DCF] Fair Price = N/A (negative equity: EV 2.07b - Net Debt 3.70b = -1.63b; debt exceeds intrinsic value)
EPS Correlation: -93.27 | EPS CAGR: -36.04% | SUE: -0.09 | # QB: 0
Revenue Correlation: -69.26 | Revenue CAGR: -1.13% | SUE: -2.55 | # QB: -2
EPS current Quarter (2026-09-30): EPS=0.27 | Chg30d=-49.90% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=0.99 | Chg30d=-22.79% | Revisions=-50% | GrowthEPS=+3.7% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=1.93 | Chg30d=-13.93% | Revisions=-62% | GrowthEPS=+95.7% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -79% (up=0, down=11)